Showing results (101-110 of 245) with videos related to
Sort By:
Pageof 25
European Urology Focus|July 21, 2017
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaGuillermo de Velasco, Kathryn P Gray, Lana Hamieh, et al.Cancer Research|December 18, 2004
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cellsRaanan Berger, Phillip G Febbo, Pradip K Majumder, et al.Proceedings of the National Academy of Sciences of the United States of America|July 12, 2005
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinaseJi Luo, Cassandra L Sobkiw, Nicole M Logsdon, et al.Cancer Research|April 24, 2013
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology CommitteeMichael Ittmann, Jiaoti Huang, Enrico Radaelli, et al.Proceedings of the National Academy of Sciences of the United States of America|February 5, 2013
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patientsBrooke M Emerling, Cyril H Benes, George Poulogiannis, et al.Oncotarget|June 2, 2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinomaXiaoen Wang, Nicolas Solban, Prateek Khanna, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trialToni K Choueiri, David J Figueroa, André P Fay, et al.Proceedings of the National Academy of Sciences of the United States of America|January 18, 2014
GRK3 is essential for metastatic cells and promotes prostate tumor progressionWenliang Li, Nanping Ai, Suming Wang, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell TherapyDavid J Einstein, Brian Halbert, Thomas Denize, et al.Cancer|May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapiesRana R McKay, Guillermo De Velasco, Lillian Werner, et al.Pageof 25